The phrase "a plethora of current" is not correct in standard English usage.
It may be intended to describe an abundance of something related to "current," but the context is unclear.
Example: "The research presented a plethora of current findings on climate change."
Alternatives: "an abundance of current" or "a wealth of current".
A PLETHORA of current television programmes attests to a widespread fascination with those who work in hospitals and those they heal, or try to.
"What's On" and "Time Out" will give you a plethora of current entertainment possibilities.
You have a plethora of current day fixations, addictions and fascinations in your notebook, waiting to fly off the page and accost your characters and mess up their lives.
When patients' comments were confusing or paradoxical, the interview would paraphrase the last comment, "do you mean..... .......... or "so you are saying...... .......... Narrative topics are not randomly chosen by patients from a plethora of past, current, and future phenomena.
It has been found this new turbine device has a plethora of advantages over current existing devices, with the simplicity and robustness that has kept the pump in use for centuries acting in its favour.
Whether caused by microbes or an unknown etiology, the complex cytokine milieu of an intestinal inflammatory response provides a plethora of information about the current disease state.
DRMs have been subject to a plethora of investigations and the current paradigm predicts that DRMs are typically enriched in cholesterol and saturated phospholipids [9].
'University is the best few years of your life, enjoy it while it lasts and make the most of it - time goes so fast' - all examples of a plethora of clichés that potential and current students are constantly blasted with.
It is evident that molecular subtype, MIPI (Hoster et al, 2008) and other biological factors need to be tested as potential companion biomarkers to enable individualized treatment selection among the plethora of current treatment strategies.
In addition to the plethora of current randomised, controlled trials, various nonrandomised clinical trials will explore the potential efficacy and safety of trastuzumab, bevacizumab, sorafenib, and erlotinib in combination with an AI as first-line or second-line therapy, and one trial will test the combination of anastrozole, fulvestrant and gefinitib in the neoadjuvant setting.
In order to tackle the current biodiversity crisis, a plethora of tempting shortcuts, such as the surrogate species approach, have recently been used to pinpoint important areas for protection.
